Johnson & Johnson (NYSE:JNJ) Shares Sold by Nordwand Advisors LLC

Nordwand Advisors LLC lowered its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 22.5% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 591,684 shares of the company’s stock after selling 171,378 shares during the period. Johnson & Johnson comprises about 35.3% of Nordwand Advisors LLC’s portfolio, making the stock its 2nd biggest holding. Nordwand Advisors LLC’s holdings in Johnson & Johnson were worth $85,569,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of the business. BBR Partners LLC increased its holdings in Johnson & Johnson by 3.2% in the 4th quarter. BBR Partners LLC now owns 28,355 shares of the company’s stock worth $4,101,000 after purchasing an additional 881 shares in the last quarter. West Family Investments Inc. increased its holdings in Johnson & Johnson by 11.1% in the 4th quarter. West Family Investments Inc. now owns 10,795 shares of the company’s stock worth $1,561,000 after purchasing an additional 1,076 shares in the last quarter. Destination Wealth Management increased its holdings in Johnson & Johnson by 1.2% in the 4th quarter. Destination Wealth Management now owns 271,859 shares of the company’s stock worth $39,316,000 after purchasing an additional 3,322 shares in the last quarter. Ashton Thomas Private Wealth LLC increased its holdings in Johnson & Johnson by 12.7% in the 4th quarter. Ashton Thomas Private Wealth LLC now owns 50,662 shares of the company’s stock worth $7,327,000 after purchasing an additional 5,728 shares in the last quarter. Finally, Strategic Family Wealth Counselors L.L.C. increased its holdings in Johnson & Johnson by 14.8% in the 4th quarter. Strategic Family Wealth Counselors L.L.C. now owns 3,497 shares of the company’s stock worth $506,000 after purchasing an additional 450 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the company. Argus raised Johnson & Johnson to a “strong-buy” rating in a report on Friday, January 24th. Leerink Partners decreased their price target on Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating for the company in a research note on Thursday, January 23rd. Stifel Nicolaus decreased their price target on Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating for the company in a research note on Thursday, January 23rd. Wells Fargo & Company decreased their price target on Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating for the company in a research note on Thursday, January 23rd. Finally, Bank of America increased their price target on Johnson & Johnson from $159.00 to $171.00 and gave the company a “neutral” rating in a research note on Wednesday. Nine investment analysts have rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $171.33.

Johnson & Johnson Trading Up 0.6 %

NYSE JNJ opened at $166.81 on Friday. The business has a 50 day simple moving average of $152.95 and a 200 day simple moving average of $156.30. Johnson & Johnson has a one year low of $140.68 and a one year high of $169.99. The stock has a market capitalization of $401.61 billion, a P/E ratio of 25.08, a P/E/G ratio of 2.56 and a beta of 0.47. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, beating analysts’ consensus estimates of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The firm had revenue of $22.52 billion during the quarter, compared to analysts’ expectations of $22.44 billion. During the same quarter last year, the firm posted $2.29 earnings per share. The company’s revenue for the quarter was up 5.3% compared to the same quarter last year. Research analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th were paid a $1.24 dividend. The ex-dividend date was Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a yield of 2.97%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 74.59%.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, EVP Timothy Schmid sold 403 shares of the firm’s stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total value of $62,928.45. Following the completion of the sale, the executive vice president now owns 15,098 shares of the company’s stock, valued at approximately $2,357,552.70. This trade represents a 2.60 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, VP Robert J. Decker sold 6,999 shares of the firm’s stock in a transaction that occurred on Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total value of $1,160,994.12. Following the completion of the sale, the vice president now directly owns 21,001 shares of the company’s stock, valued at $3,483,645.88. This trade represents a 25.00 % decrease in their position. The disclosure for this sale can be found here. Insiders own 0.16% of the company’s stock.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.